What is NDC 71288-040?

71288-040 is the product NDC for Citric Buffered Normal Saline (anhydrous citric acid), Anhydrous citric acid 166 mg/270mL injection, solution, listed with the FDA by Meitheal Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Citric Buffered Normal Saline (Anhydrous citric acid).

Meitheal Pharmaceuticals Inc., NDC labeler code 71288. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Citric Buffered Normal Saline?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Citric Buffered Normal Saline NDC 71288-040

NDC codes

FDA NDC Directory

Product NDC (as listed)71288-040Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71288-0040Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71288-040-65	7128800406571288004065	6 BAG in 1 CARTON (71288-040-65) / 270 mL in 1 BAG (71288-040-64)Marketed from Sep 9, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Citric Buffered Normal Saline
Generic name (nonproprietary): anhydrous citric acid
Active ingredients: Anhydrous citric acid — 166 mg/270mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Meitheal Pharmaceuticals Inc.NDC labeler code 71288
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211673
Marketing start: Sep 9, 2019
Listing expires: Dec 31, 2027
Other FDA classes: Acidifying Activity (Mechanism)Calcium Chelating Activity (Mechanism)Decreased Coagulation Factor Activity (Physiologic effect)
Identifiers: Product ID 71288-040_b9951406-492b-4420-89cc-24fd655824b3SPL ID b9951406-492b-4420-89cc-24fd655824b3SPL set ID eb972ea8-7502-422e-84bb-66cb8e93ca06RxCUI 2198948, 2198953, 2198961, 2198966, 2747671, 2747672UNII HDN0B924X4, XF417D3PSL
Pharmacologic class: Anti-coagulant; Calculi Dissolution Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471288004065 followed by a unit qualifier and the quantity

Package 71288-0040-65. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 22, 2026.

Indications (excerpt from the label)

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. ( 1.1 ) To reduce the development of drug resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Community-Acquired Bacterial Pneumonia (CABP) XENLETA is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae , Staphylococcus aureus (methicillin-sus…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71288-040

What is NDC 71288-040?: 71288-040 is the product NDC for Citric Buffered Normal Saline (anhydrous citric acid), Anhydrous citric acid 166 mg/270mL injection, solution, listed with the FDA by Meitheal Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Citric Buffered Normal Saline (Anhydrous citric acid).
What is the active ingredient?: Anhydrous citric acid.
Who is the labeler?: Meitheal Pharmaceuticals Inc., NDC labeler code 71288. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Citric Buffered Normal Saline?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under NDA 211673

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211673
Product	Strength	Form · route	Labeler	Product NDC
Xenletalefamulin acetate	Lefamulin acetate 150 mg/15mL	Injection, SolutionIntravenous	Meitheal Pharmaceuticals Inc.	71288-039

Citric Buffered Normal Saline (Anhydrous citric acid) NDC 71288-040